Search results
Drug shortages keep growing, and older, injectable medicines are among the most vulnerable
Anchorage Daily News· 5 days agoErin Fox has tracked drug shortages for more than 20 years, and she sees no easy solutions for what...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 3 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
Zacks via Yahoo Finance· 1 day agoContraction in gross and operating margins does not bode well. Estimates Trend The company has been...
Weight-Loss Drugs Dangers Explained: Zepbound, Mounjaro Maker Warn Of Coming Counterfeit Lawsuit
Forbes· 3 days agoThe company says some wellness centers and websites are selling unauthorized and counterfeit...
3 No-Brainer Stocks to Buy for Under $100 Right Now
Motley Fool via Yahoo Finance· 7 hours agoThe company acquired Arena, Biohaven, and Reviral in 2022, and bought Seagen last year. Management... 10 stocks that made the cut could produce monster...
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Zacks via Yahoo Finance· 1 day agoThe stock has risen 453% in the past five years, mainly on the success of its drug semaglutide, a...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 5 hours agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
Appeals court finds 'Obamacare' pillar unconstitutional in suit over HIV-prevention drug
NBC Universal via AOL· 21 hours agoBut should the task force lose its insurance-coverage...could gain approval for use as PrEP by 2025...
Drug Names: The machinations behind the monikers
Quartz· 4 days agoIn fact, naming a prescription drug can take a manufacturer up to four years, as a set of three monikers per medicine must run the gauntlet of several regulatory agencies.
Gateway - Quartz
Quartz· 4 days agoThe first biosimilar to enter the market is Amgen’s Amjevita, which was launched in the US on Jan. 31, 2023. The drug will be available in the US at two different